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http://dx.doi.org/10.1016/j.ccr.2012.11.013SUMMARYInflammatory bowel disease is an important risk factor for colorectal cancer. We show that sphingosine-1-
phosphate (S1P) produced by upregulation of sphingosine kinase 1 (SphK1) links chronic intestinal inflam-
mation to colitis-associated cancer (CAC) and both are exacerbated by deletion of Sphk2. S1P is essential
for production of the multifunctional NF-kB-regulated cytokine IL-6, persistent activation of the transcription
factor STAT3, and consequent upregulation of the S1P receptor, S1PR1. The prodrug FTY720 decreased
SphK1 and S1PR1 expression and eliminated the NF-kB/IL-6/STAT3 amplification cascade and development
of CAC, even in Sphk2/ mice, and may be useful in treating colon cancer in individuals with ulcerative
colitis. Thus, the SphK1/S1P/S1PR1 axis is at the nexus between NF-kB and STAT3 and connects chronic
inflammation and CAC.INTRODUCTION
Chronic inflammation is now recognized to have decisive roles in
the pathogenesis of cancer (Grivennikov et al., 2010). Inflamma-
tory bowel diseases (IBDs) are a salient example of the link
between chronic inflammation and cancer, and one of the
consequences of persistent inflammation of the colon or ulcera-
tive colitis (UC) is an increased risk for developing colorectal
cancer (Ullman and Itzkowitz, 2011). Animal models that
reproduce many aspects of the human disease have provided
important clues to the critical roles of inflammatory mediators
and molecular events leading to the development of colitis-
associated cancer (CAC) (Saleh and Trinchieri, 2011) and haveSignificance
The proinflammatory cytokines TNF-a and IL-6 and their do
emerged as critical regulators linking inflammation to cancer
formation of the bioactive sphingolipid mediator S1P, and su
role in maintaining persistent activation of these transcription
leads to chronic inflammation and CAC development. The im
S1P/S1PR1 axis and eliminated the NF-kB/IL-6/STAT3 amp
blocked CAC progression even after tumors were established
in individuals with chronic inflammation.
Chighlighted the key roles played by the master transcription
factors NF-kB and signal transducer and activator of transcrip-
tion-3 (STAT3) (Bollrath et al., 2009; Greten et al., 2004; Griven-
nikov et al., 2009). NF-kB activation in intestinal epithelial cells
(IECs) promotes survival pathways that are required for growth
of premalignant cells and subsequent formation of tumors
(Greten et al., 2004). Although loss of STAT3 and NF-kB in
IECs has been associated with increased inflammation (Greten
et al., 2004; Grivennikov et al., 2009), activation of NF-kB
in myeloid-derived inflammatory cells, on the other hand,
enhances inflammation in the tumor microenvironment, mainly
by increasing expression of proinflammatory cytokines, such
as TNF-a and IL-6, that in turn stimulate proliferation of tumorwnstream master transcription factors NF-kB and STAT3
. We demonstrated that upregulation of SphK1 expression,
bsequent activation of its S1PR1 receptor play an essential
factors in a malicious feed-forward amplification loop that
munosuppressive drug FTY720 interfered with the SphK1/
lification cascade and development of CAC. FTY720 also
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2004; Popivanova et al., 2008). It was also elegantly demon-
strated that IL-6 enhances both initiation and progression of
CAC and that STAT3 activation downstream of IL-6 has an
essential role in intestinal mucosal regeneration after injury and
in the development of CAC (Bollrath et al., 2009; Grivennikov
et al., 2009). Expression of TNF-a and IL-6 and activation of
NF-kB and STAT3 are also increased in patients with active
UC and in those who progressed to colorectal cancer (Kim
et al., 2008; Li et al., 2010; Popivanova et al., 2008).
There is growing evidence that S1P, a pleiotropic bioactive
sphingolipid metabolite formed inside cells by two closely
related sphingosine kinases, SphK1 and SphK2, is involved in
inflammation and cancer (Pyne and Pyne, 2010; Spiegel and
Milstien, 2011). S1P regulates numerous cellular processes
important for cell growth, survival, invasion, lymphocyte traf-
ficking, vascular integrity, and cytokine and chemokine pro-
duction, among others. S1P and SphK1 have long been
implicated in the actions of proinflammatory cytokines, such as
TNF-a (Pettus et al., 2003; Xia et al., 1998). TNF-a activates
and translocates SphK1 to the plasma membrane, where it
catalyzes the formation of S1P (Pitson et al., 2003). S1P in turn
signals through five G protein-coupled receptors (S1PR1–5).
This ‘‘inside-out signaling’’ by S1P is thought to promote certain
TNF-a functions (De Palma et al., 2006; Scherer et al., 2010).
However, it was recently demonstrated that SphK1 and intra-
cellular S1P also play a direct role in TNF-a signaling and the
canonical NF-kB activation pathway important in inflammatory,
antiapoptotic, and immune processes (Alvarez et al., 2010).
Interestingly, the S1P receptor S1PR1 was recently identified
as a key component for persistent activation of STAT3 in tumors
(Lee et al., 2010; Liu et al., 2012). It was shown that STAT3
induced S1PR1 expression and, conversely, the presence of
S1PR1 in the tumor and associated immune cells was required
for persistent STAT3 activation, tumor growth, and metastases
(Lee et al., 2010), yet the involvement of S1P, the only known
endogenous S1PR1 activator, has not been investigated.
Expression of SphK1 is elevated in the colons of patients with
UC (Snider et al., 2009) and colon cancer (Kawamori et al., 2009),
and deletion of Sphk1 reduced aberrant crypt formation and
tumor development in a mouse CAC model (Kawamori et al.,
2009). However, the molecular mechanisms by which S1P
produced by SphK1 promotes early or late stages of CAC have
not been elucidated. Because little is still known of the function
of the other sphingosine kinase isoenzyme SphK2, in this study,
we investigated its involvement in colitis and CAC. We also
elucidated the roles of the SphK1/S1P/S1PR1 axis in the NF-
kB/IL-6/STAT3 amplification cascade and development of CAC.
RESULTS
SphK2 Deficiency Exacerbates Colitis-Associated
Tumorigenesis
To examine the involvement of SphK2 in CAC development,
wild-type (WT) and Sphk2/ mice were injected with the
colonotropic mutagen azoxymethane (AOM) followed by three
rounds of oral administration of the luminal toxin dextran sodium
sulfate (DSS) to trigger chronic inflammation (Figure 1A). In
contrast to the protective effects of Sphk1 deletion (Kawamori108 Cancer Cell 23, 107–120, January 14, 2013 ª2013 Elsevier Inc.et al., 2009), knockout of Sphk2 markedly increased tumor
number (Figure 1B) and tumor size (Figure 1C), with a concomi-
tant increase in tumor load (Figure 1D). There was also a large
increase in adenomas with a high grade of dysplasia in
Sphk2/ mice (Figures 1E and 1F), whereas most of the tumors
in WT mice were low-grade dysplasias. Consistent with the
profound effect on tumor size, there was a significant increase
in proliferation determined by Ki-67 staining in the Sphk2/
mice (Figures 1G and 1H). In agreement with the causal role of
cyclooxygenase-2 (COX-2) in colon carcinogenesis (Oshima
et al., 1996), immunohistochemical staining revealed elevated
levels of COX-2 in Sphk2/ mice, mainly in infiltrating inflam-
matory cells (Figure 1I).
Increased Severity of DSS-Induced Colitis in Sphk2–/–
Mice
Because inflammation plays a critical role in tumorigenesis (Gri-
vennikov et al., 2010), we next examined whether the increased
tumor multiplicity and load in Sphk2/ mice could be due to
increased intestinal inflammation. To this end, mice were sub-
jected to a single 5-day course of DSS to induce acute colitis.
Sphk2/ mice showed more severe colitis, with significantly
greater weight loss (Figure 2A), more extensive colon shortening
(Figure 2B), and increased Hemoccult and diarrhea scores than
WT littermates (data not shown). In agreement, histopathological
analysis revealed more severely damaged colonic mucosa with
extensive loss of crypt structures and epithelial cell denudation,
larger areas of ulceration, and more extensive infiltration of
inflammatory cells (Figure 2C), which was also reflected in the
pathological assessment of colitis severity scores (Figure 2D).
This severe colitis was not due to dysfunction of mucosal integ-
rity because mucosal barrier function determined with FITC-
dextran during the induction phase of colitis was similar in WT
and Sphk2/ mice (Figures S1A and S1B available online).
There were also no significant differences in numbers of acti-
vated Th cells or Tregs between WT and Sphk2/ mice, even
during acute colitis (Figures S1C–S1E).
Deletion of SphK2 Enhances SphK1 Expression
S1P has been implicated in the development of DSS-induced
colitis, and deletion of SphK1 reduces colitis severity (Snider
et al., 2009). Indeed, we found that circulating S1P levels in WT
mice were increased during acute colitis. Surprisingly, however,
basal S1P levels in the circulation and colon were greater in
Sphk2/mice and were increased even further by DSS (Figures
2E and 2F). SphK1 expression at the message and protein
level in the colon was also elevated in Sphk2/ mice compared
to littermates and markedly increased during colitis (Figure 2G
and 2H), indicating that the increases in S1P and severity
of colitis in Sphk2/ mice are likely due to upregulation of
SphK1, especially because there were no changes in expression
or activity of the S1P metabolic enzymes, S1P phosphatase and
S1P lyase (Figure S1F).
Upregulation of SphK1 was observed in Sphk2/ MEFs
(Figure S2A) or after downregulating SphK2 in cultured cells
(Gao and Smith, 2011). S1P produced in the nucleus by SphK2
inhibits HDAC1/2 activity similar to classical HDAC inhibitors,
and, conversely, downregulation of SphK2 and reduction of
nuclear S1P increases HDAC activity and concomitantly
Figure 1. Colitis-Associated Tumor Development Is Increased in Sphk2–/– Mice
(A) Schematic overview of the CAC regimen. Sphk2/mice and WT littermates were injected with AOM followed by three cycles of 2.5% DSS in drinking water.
Intestinal tumors were analyzed on day 140.
(B–D) Tumor number (B), tumor size (C), and tumor load, the sum of the diameters of all tumors in a given mouse (D), were determined.
(E and F) Representative H&E-stained sections from WT and Sphk2/ mice. (F) Higher magnification images of the boxed areas in (E).
(G and H) Proliferation was determined by Ki-67 staining (H) and percentage of Ki-67 positive cells within colonic crypts calculated (G).
(I) COX-2 expression was determined by immunohistochemistry.
Data are means ± SEM (n = 6). *p < 0.05, **p < 0.005. Scale bars, 100 mm.
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colons from Sphk2/ mice have reduced histone acetylations
(Figure 3A). Because it was suggested that SphK1 expression
is transcriptionally regulated by c-Jun (Paugh et al., 2009; Sobue
et al., 2008), a component of AP-1 transcription factor whose
expression is regulated by HDACs (Yamaguchi et al., 2005), we
examined the role of c-Jun in the paradoxical increase of
SphK1 expression due to Sphk2 deletion. The colons from
Sphk2/ mice have high levels of c-Jun and phospho-c-Jun
(Figure 3A). Sphk2/ MEFs also have higher expression of
protein and mRNA for both c-Jun and SphK1 (Figures 3B and
S2A). Moreover, the pan HDAC inhibitors, trichostatin A (TSA)
and suberoylanilide hydroxamic acid (SAHA), suppressed the
induction of c-Jun transcription, in agreement with others (Lind-
stro¨m et al., 2008; Yamaguchi et al., 2005), and also blocked
induction of Sphk1 (Figure 3B). Several putative AP-1 regulatory
elements in the 8 kb-long 50-flanking region of the Sphk1 gene
have been identified (Paugh et al., 2009) (Figure S2B). Indeed,
reporter activity of the Sphk1 promoter containing the AP-1
site, but not a construct without this site, was markedly inducedCby PMA. This Sphk1 promoter activity was blocked by not
only a JNK inhibitor (SP600125) but also by SAHA (Figure S2B).
Altogether, these data suggest that deletion of Sphk2 and lack
of HDAC inhibition by S1P increase the induction of c-Jun and
its target gene Sphk1.
Upregulation of the SphK1/S1P/S1PR1 Axis
and Activation of NF-kB and STAT3 in Severity
of Acute Colitis
The transcription factor NF-kB has long been known to play
a critical role in acute inflammation and colitis (Karin, 2009).
Because S1P produced by SphK1 has been implicated as an
essential regulator of the canonical NF-kB pathway (Alvarez
et al., 2010), activation of NF-kB was next examined. NF-kB
was constitutively activated in Sphk2/ colon, as shown by
increased phosphorylation and nuclear translocation of its p65
subunit (Figure 3C), and was markedly stimulated even further
during colitis development, correlating with the elevation of
SphK1 and S1P (Figures 2F–2H). Consistent with the increased
NF-kB activation, serum levels of the proinflammatory cytokineancer Cell 23, 107–120, January 14, 2013 ª2013 Elsevier Inc. 109
Figure 2. Deletion of SphK2 Increases S1P and the Severity of Colitis
(A–D) Acute colitis was induced in Sphk2/mice andWT littermates with 5%DSS in drinking water for 5 days followed by recovery for 5 days on normal drinking
water. Changes in body weight (A), colon shortening (B), mucosal histology examined by H&E staining (C, scale bar, 100 mm), and colitis severity scores were
determined (D) in a double-blind manner. In (A), (B), and (D), data are means ± SEM (n = 6). *p < 0.05, **p < 0.001 compared to WT treated with DSS.
(E and F) S1P in serum (E) and colon (F) was measured by LC-ESI-MS/MS.
(G and H) Expression of SphK1 and SphK2 in colons was determined by QPCR (G) and western blotting (H).
In (E)–(G), data are means ± SD (n = 3). *p < 0.05, **p < 0.005.
See also Figure S1.
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Sphk2/mice and were further increased during DSS challenge
(Figures 3D and 3E). Likewise, TNF-a, but not IL-17, IFN-g, or
IL-10, release from Sphk2/ colonic mucosa was increased
compared to littermate controls (Figure S2C). A dramatic upre-
gulation of IL-6 mRNA expression was also evident in colonic
mucosa (Figure 3F). The important functions of IL-6 are exerted
via activation of STAT3 (Bollrath et al., 2009; Grivennikov et al.,
2009). Indeed, nuclear accumulation of phosphorylated STAT3
was already evident in the Sphk2/ colonic mucosa and was
considerably increased by DSS compared to WT (Figure 3C).
In agreement with the view that STAT3 is a direct regulator of
expression of S1PR1 (Lee et al., 2010; Liu et al., 2012), S1PR1
expression was also elevated in Sphk2/ colonic mucosa and
dramatically enhanced during acute colitis (Figure 3G).
Upregulation of S1PR1 expression could result in its constitu-
tive activation (Pyne and Pyne, 2010). However, upregulation
of SphK1 in Sphk2/ mice leads to increased levels of S1P
in serum and colon (Figures 2E and 2F). Moreover, SK1-I,
a SphK1 inhibitor (Paugh et al., 2008), significantly reduced the
severity of DSS-induced colitis (Figures S2D–S2F), the sustained
activation of NF-kB and STAT3 (Figure S2G), and IL-6 ex-
pression in the colonic mucosa of DSS-challenged Sphk2/
mice (Figure S2H), concomitantly with reduction of S1P (Fig-
ure S2I). In addition, W146, a competitive S1PR1 antagonist110 Cancer Cell 23, 107–120, January 14, 2013 ª2013 Elsevier Inc.that does not have inverse agonist activity (Sanna et al., 2006),
also suppressed DSS-induced weight loss and severity of colitis
in Sphk2/ mice (Figures S2J–S2L), the sustained activation of
STAT3 and IL-6 expression (Figures S2M–S2O), as well as the
basal hyperactivation of STAT3 and NF-kB in naive Sphk2/
mice (Figure S2P). Taken together, these results suggest that,
although expression of S1PR1 is increased in Sphk2/ mice,
it is not constitutively activated, and highlight the importance
of increased formation of S1P, the ligand for S1PR1.
SphK2 Deficiency in Hematopoietic Cells Contributes
to Colitis Severity, IL-6 Production, and Activation
of STAT3 and NF-kB
To determine whether the effect of SphK2 deficiency on colitis
severity and activation of NF-kB and STAT3 was due to hemato-
poietic cells or nonhematopoietic cells (e.g., IECs), and to
gain insight into the cellular source of IL-6, we generated
reciprocal bone marrow chimeras by adoptively transferring
bone marrow into lethally irradiated recipients. Chimerism, as
determined by flow cytometric analysis of the CD45.1 (Ly5.1)
and CD45.2 (Ly5.2), was approximately 90%–95%. After DSS
challenge, body weight loss, colitis severity with inflammatory
cell infiltration (Figures 4A–4D), and phosphorylation of STAT3
and p65 were greatly increased (Figure 4F) when Sphk2/
hematopoietic cells were transplanted into WT mice (KO/WT).
Figure 3. Severity of Colitis in Sphk2–/– Mice Correlates with Upregulation of SphK1, S1PR1, and IL-6, and Activation of NF-kB and STAT3
(A) Colonic lysates or nuclear extracts from Sphk2/ mice and WT littermates were analyzed by immunoblotting with the indicated antibodies.
(B) WT and Sphk2/MEFs were pretreated without or with SAHA, TSA, or SP600125, stimulated without or with PMA for 3 hr, andmRNA levels were determined
by QPCR.
(C–G) Colitis was induced with 5% DSS. Equal amounts of colonic nuclear extracts were analyzed by western blotting with the indicated antibodies (C). IL-6 in
serum (D) and secreted from colon (E) was measured by ELISA. Expression of IL-6 (F) and S1PR1 (G) was determined in colons by QPCR.
Data are means ± SD. *p < 0.05, **p < 0.005.
See also Figure S2.
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and NF-kB were markedly decreased by transplantation of
WT hematopoietic cells into Sphk2/ mice (WT/KO) (Figures
4A–4F). Similarly, IL-6 expression was increased in the colonsCof KO/WT mice compared to WT/KO or WT/WT mice
(Figure 4E). Moreover, intracellular cytokine staining and flow
analysis suggest that macrophages and dendritic cells are the
major producers of IL-6 in KO/WT mice (Figure 4G). Theseancer Cell 23, 107–120, January 14, 2013 ª2013 Elsevier Inc. 111
Figure 4. SphK2 Deficiency in Hemato-
poietic Cells Increases Colitis Severity,
Activation of STAT3 and NF-kB, and IL-6
Production
(A–F) Acute colitis was induced in bone marrow
chimeric mice with 2.5% DSS. (A) Changes in
body weight. (B) Maximum percentage loss of
body weight. *p < 0.05. (C) Colitis severity scores.
*p < 0.05. (D) Mucosal histology examined by
H&E staining. Scale bar, 100 mm. (E) Immunohis-
tochemistry staining for IL-6. Scale bar, 50 mm. (F)
Colonic lysates analyzed by immunoblotting.
(G) Spleen cells were stimulated with PMA and
ionomycin and intracellular IL-6 staining in T cells
(CD3+), B cells (B220+), macrophages (Macs,
CD11b+CD11c), and dendritic cells (DCs,
CD11b+CD11c+) was analyzed by FACS. *p <
0.05, **p < 0.01, compared to WT/WT.
(H and I) WT and Sphk2/mice were subjected to
the CAC regimen. (H) Immunohistochemical
staining of IL-6 expression in CAC-bearing mice.
Scale bar, 50 mm. (I) Intracellular IL-6 staining was
determined by FACS as in (G). *p < 0.05, **p < 0.01,
compared to WT.
Data are means ± SEM.
See also Figure S3.
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than IECs, orchestrate these responses.
Consistent with several studies showing that IL-6 is needed
continuously for stimulation of CAC tumor growth (Becker
et al., 2004; Grivennikov et al., 2009; Schiechl et al., 2011), in
CAC-bearing Sphk2/ mice, strong IL-6 expression was de-
tected in infiltrating immune cells with weaker, but still enhanced,
expression compared to WT in IECs (Figure 4H). Confocal
fluorescence microscopy was then utilized to simultaneously112 Cancer Cell 23, 107–120, January 14, 2013 ª2013 Elsevier Inc.visualize IL-6 and macrophages or
T cells during colitis and CAC. Enhanced
IL-6 expression was detected predomi-
nantly in infiltrating macrophages and
much less in T cells in the colonic mucosa
of DSS-challenged Sphk2/ than in
WT mice (Figure S3A). Moreover, during
the late phase of CAC, both macro-
phages and T cells were increased in
the adenoma leukocyte infiltrates of
Sphk2/ mice (Figure S3B) and IL-6
was strongly expressed in macrophages,
dendritic cells, and in T cells, albeit to a
lesser extent (Figures 4I and S3C). Con-
sistent with the role of IL-6 in Th17 lineage
differentiation, T cells from Sphk2/
lymph nodes during colitis and CAC
secreted slightly higher levels of IL-17
(Figures S1E, S3D, and S3E).
The S1PR1 Modulator FTY720
Suppresses Colitis in Sphk2–/– Mice
Because enhanced S1PR1 levels recip-
rocally activate STAT3, leading to itspersistent activation and upregulation of IL-6 expression (Lee
et al., 2010), we therefore sought to examine the effects of
interfering with S1PR1 functions and this feed-forward ampli-
fication loop. To this end, we treated mice with the immunosup-
pressant FTY720, known to be phosphorylated in vivo to an
S1P mimetic that modulates the immune system by acting as
a functional antagonist of S1PR1 and inducing its internalization
and degradation (Brinkmann et al., 2010). In agreement with
previous studies (Daniel et al., 2007; Deguchi et al., 2006), daily
Cancer Cell
S1P Links STAT3 Activation, Colitis, and CACtreatment with FTY720 suppressed colitis symptoms inWTmice,
including weight loss, colon shortening, and colonic mucosa
damage and severity (Figures 5A, 5B, and S4A). Although it has
been suggested that SphK2 is essential for FTY720-phosphate
formation and function in vivo (Kharel et al., 2005; Zemann
et al., 2006), unexpectedly, FTY720 also significantly reduced
colitis severity in mice that do not express this enzyme (Figures
5A, 5B, and S4A). Surprisingly, FTY720 also elicited lymphopenia
in Sphk2/ mice (Figure 5B). Consistent with these in vivo
effects, significant levels of FTY720-phosphate were present in
serum and colons from Sphk2/ mice (Figure 5C), albeit less
than in WT mice. Moreover, inhibition of SphK1 with SK1-I sig-
nificantly decreased phosphorylation of FTY720 in the colons of
Sphk2/ mice (Figure S4B), suggesting that SphK1 in addition
to SphK2 can also phosphorylate FTY720 in vivo.
FTY720 Interferes with the SphK1/S1P/S1PR1
Feed-Forward Loop that Leads to Persistent NF-kB
and STAT3 Activation and IL-6 Production
Previous studies suggest that FTY720 is also an inhibitor of
SphK1 and induces its proteasomal degradation (Lim et al.,
2011; Tonelli et al., 2010). FTY720 almost completely abrogated
the large increase in SphK1 protein in the inflamed colon of
WT mice induced by DSS treatment, as well as dramatically
decreasing the remarkable enhancement in SphK1 expression
in Sphk2/ mice (Figure 5D). Concomitantly, FTY720 adminis-
tration also prevented the increased S1P levels in the circulation
and the colon induced by DSS treatment (Figure 5E).
It was then of relevance to examine the effect of targeting the
SphK1/S1P/S1PR1 axis with FTY720 on the NF-kB/IL-6/STAT3
cascade, a central node in the development of colitis and CAC
(Grivennikov et al., 2010). FTY720 not only reduced the sustained
phosphorylation of the p65 NF-kB subunit in Sphk2/mice with
acute colitis (Figure 5F) but also dramatically decreased the
elevated levels of IL-6 and S1PR1 protein, and the activation of
their downstream effector STAT3 (Figures 5F–5J), as well as
recruitment of macrophages (Figure S4A). Similar to S1PR1,
expression of other STAT3-dependent gene products that
were significantly increased in these mice, such as c-Myc, was
also suppressed by FTY720 (Figure 5F). To gain further insight
into the positive feedback loop whereby S1PR1 elevation acti-
vates STAT3 (Lee et al., 2010), we explored the involvement of
the tyrosine kinase Src, which is activated downstream of
ligation of S1PR1 (Rakhit et al., 1999) and has been shown to
phosphorylate and activate STAT3 (Yu et al., 1995). Consistent
with activated S1PR1 signaling in the Sphk2/ colon, higher
levels of Src phosphorylation were observed in these mice
(Figure 5F). Hyperactivation of Src in the colonic mucosa of
mice with acute colitis was also overcome by FTY720 treatment
(Figure 5F). Nevertheless, treatment of naive Sphk2/ mice
with anti-IL-6 neutralizing antibody, but not with PP1, a Src
inhibitor, decreased STAT3 hyperactivation (Figure S4C), sug-
gesting that excess IL-6 is the major contributor to STAT3
activation in these mice.
FTY720 Suppresses Colorectal Tumorigenesis
Associated with Chronic Colitis
Because our data suggest that FTY720 alleviates colitis
severity by impeding the positive feedback loop initiated byCSphK1 and S1P signaling, we next assessed the potential
efficacy of FTY720 in prevention of the development and
progression of CAC. Administration of FTY720 during CAC
induction drastically reduced tumor size, multiplicity, and load
(Figures 6A–6D). FTY720 was also very efficacious in mice
deficient in SphK2, which exacerbates colitis-associated
tumorigenesis (Figures 6B–6D). Moreover, the few polypoid
lesions protruding into the lumen that developed in the small
proportion of these FTY720-treated mice were markedly
smaller (Figure 6C).
To determine whether the effects of FTY720 are mainly due to
suppression of inflammation during early CAC induction or
whether it can also impact tumor progression, FTY720 was
administered to mice only after the last DSS cycle (Figure 6E).
Remarkably, even when FTY720 was administered over this
shorter and delayed time period, it significantly reduced the
number and size of macroscopic tumors (Figures 6F and 6G)
and average tumor load (Figure 6H) compared to PBS-treated
WT mice. Although a similar tendency was observed in
Sphk2/ mice treated with FTY720 at this late stage of CAC, it
did not reach statistical significance (Figures 6F–6H).
In agreement with the profound effects of FTY720 when
administered to WT mice during CAC induction or even after
the last DSS cycle, nuclear Ki-67 staining was reduced and
restricted to the crypt bases in these mice (Figure 7A), whereas
colorectal adenomas from PBS-treated WT and Sphk2/ mice
showed large increases in proliferation rates compared to
normal mucosa, in which only about 20% of cells were Ki-67
positive (Figures 7A and 7B). Importantly, treatment with
FTY720 at the late stage of CAC also significantly reduced the
proliferation rate of Sphk2/ tumors (Figures 7A and 7B). These
results suggest that FTY720 can also affect tumor growth and
development.
This prompted us to examine the effect of FTY720 on activa-
tion of STAT3, which is critical for proliferation and survival of
IECs and development of CAC (Bollrath et al., 2009; Grivennikov
et al., 2009). Immunohistochemical analysis revealed that phos-
phorylated STAT3 was more strongly expressed in infiltrating
inflammatory cells and in nuclei of IECs of CAC adenomas
from Sphk2/ mice (Figures 8A and S5A). Administration of
FTY720 even after the last DSS cycle abolished nuclear
p-STAT3 staining in tumors from both WT and Sphk2/ mice
(Figure 8A), and in the much fewer infiltrating cells (Figure S5A),
withmarked decreases in IL-6 expression (Figure S5B). Similarly,
the increased p-p65 staining in IECs of CAC adenomas from
Sphk2/ mice was reduced after this late treatment with
FTY720 (Figure S5A). As with DSS-induced colitis, enhanced
expression of SphK1 was clearly evident by immunohistochem-
istry in CAC adenomas of Sphk2/ mice, and higher levels of
SphK1 were also observed in both IECs and infiltrating immune
cells (Figure 8B). Late FTY720 administration also drastically
reduced elevated SphK1 in CAC adenomas and in distal IECs,
as well as in the few infiltrating cells (Figure 8B). Finally, late
treatment with FTY720 also decreased the elevated levels of
S1PR1 observed in CAC adenomas from Sphk2/ mice (Fig-
ure 8C). Thus, FTY720 curtails the amplification loop involving
SphK1, S1P, and S1PR1 leading to persistent phosphorylation
of STAT3 and can suppress development of CAC even when
tumors are already present.ancer Cell 23, 107–120, January 14, 2013 ª2013 Elsevier Inc. 113
Figure 5. FTY720 Suppresses Colitis, S1P Signaling, and Persistent STAT3 Activation in Sphk2–/– Mice
(A–J) Mice were given PBS or FTY720 daily during colitis regimen.
(A) Changes in body weight.
(B) Colitis severity scores and lymphocyte counts in blood were determined on day 10. In (A) and (B), data are means ± SEM (n = 9). *p < 0.05, **p < 0.005
compared to mice treated with PBS.
(C) Serum and colon levels of FTY720 and FTY720-P in WT and Sphk2/ mice were measured by LC-ESI-MS/MS.
(D and F) Colonic lysates were analyzed by immunoblotting with the indicated antibodies.
(E) S1P in serum and colon was measured by LC-ESI-MS/MS.
(legend continued on next page)
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Figure 6. FTY720 Represses Development of CAC
(A–D) Schematic overview of FTY720 administration during CAC induction.
PBS or FTY720 (0.3 mg/kg) was administered by gavage five times per week
from day 1 to day 140 (FTY720day 1–140) (A). Tumor number per mouse (B),
tumor size (C), and tumor load (D) were analyzed on day 140.
(E–H) Schematic overview of FTY720 treatment during the late stage of CAC
induction. PBS or FTY720 (0.3 mg/kg) was administered five times per
week beginning one day after the last DSS cycle (day 51) to day 120
(FTY720day 51–120) (E). Tumor number per mouse (F), tumor size (G), and tumor
load (H) were analyzed on day 140.
Data are means ± SEM, n = 7–8, *p < 0.05, **p < 0.01.
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Although substantial improvements have been made in diag-
nosis and therapy of IBD, the risk of CAC still remains high.
Significant advances have been made in recent years in under-
standing the link between chronic gastrointestinal inflammation
and cancer, particularly in deciphering the roles of the proin-
flammatory cytokines TNF-a and IL-6 and their downstream
transcription factors NF-kB and STAT3 (Ben-Neriah and Karin,
2011; Yu et al., 2009). However, negative feedback loops usually
tightly limit the duration of activation of NF-kB (Ben-Neriah and
Karin, 2011) and STAT3 (Yu et al., 2009), and it is not clear how
their persistent activation is maintained during colitis and the
progression of CAC. Our study highlights one of the previously
missing links in this intriguing puzzle of the association between(G and H) IL-6 in serum and secreted from colon was measured by ELISA.
(I and J) Expression of IL-6 and S1PR1 was determined in colons by QPCR.
In (C), (E), and (G–J), data are means ± SD. *p < 0.05, **p < 0.01.
See also Figure S4.
Cinflammation and cancer and suggests that strategies that
disrupt this link may be of clinical benefit to patients with IBD.
Here, we demonstrate that SphK1, formation of S1P, and
subsequent activation of its targets, NF-kB and S1PR1, play
an essential role in maintaining persistent activation of NF-kB
and STAT3 in a malicious feed-forward amplification loop that
leads to chronic inflammation and CAC development. SphK1 is
upregulated in patients with colon and gastric cancer, and its
expression correlates with cancer progression and poor prog-
nosis (Kawamori et al., 2009; Li et al., 2009). Similar to SphK1,
we found that S1PR1 is also markedly upregulated in murine
models of colitis and CAC. An unanticipated observation in
this study was the large basal increases in expression of
SphK1 and S1PR1 in Sphk2/ mice, which, we suggest,
provides a priming environment that augments acute colitis
and CAC. Our results suggest that myeloid cells, rather than
IECs, are the initiators and orchestrators of the enhanced colitis
and CAC observed in Sphk2/mice. During colitis, andmore so
in CAC, there was increased infiltration of macrophages and
T cells into tumor tissues of Sphk2/ mice that exhibited
enhanced expression and secretion of IL-6. Our results support
the previous conclusion that, during CAC induction, this tumor-
promoting cytokine is produced predominantly bymacrophages
and dendritic cells and, to a lesser extent, by T cells and possibly
by IECs (Grivennikov et al., 2009; Matsumoto et al., 2010;
Schiechl et al., 2011). Although recipients of Sphk2/ CD4+
T cells in an adoptive transfer model of IBD also showed more
severe colitis, it was proposed that this was due to STAT5-
mediated hyperactivity of these T cells and was independent
of S1P (Samy et al., 2007). However, a caveat to this conclusion
is that methods for measurement of low amounts of S1P in cells
and tissues have only recently been developed (Shaner et al.,
2009). In addition to increased IL-6, higher levels of TNF-a (but
not IL-17, IFN-g, or IL-10) were released from the colonic
mucosa of Sphk2/ mice. Our results suggest that these
proinflammatory cytokines, TNF-a and IL-6, are responsible for
the enhanced CAC in Sphk2/ mice acting on mutant IEC cells
to increase tumor incidence and growth through paracrine
induction of NF-kB and STAT3 and feed-forward amplification
loops (Figure 8D). STAT3 then regulates expression of many
genes involved in both cell survival and proliferation (Yu et al.,
2009) and, in addition, reciprocally upregulates transcription of
S1PR1 (Yu et al., 2009). Moreover, SphK1 and intracellular
S1P are also involved in activation of NF-kB by TNF-a, most
likely by enhancement of the E3 ubiquitin ligase activity of
TRAF2 (Alvarez et al., 2010). NF-kB and STAT3 can also act in
positive feedback loops to enhance production of cytokines
and chemokines that recruit additional immune cells that main-
tain tumor-associated inflammation (Grivennikov et al., 2010).
The importance of the direct and indirect roles of NF-kB in
tumorigenesis and production of tumor-promoting cytokines
by inflammatory cells emerged from gene deletion studies in
which inactivation of IKKb in myeloid cells reduced tumor growth
and blocked production of IL-6 and other cytokines in CACancer Cell 23, 107–120, January 14, 2013 ª2013 Elsevier Inc. 115
Figure 7. Colonic Epithelial Cell Proliferation in CAC Is Repressed by Treatment with FTY720
(A and B) Colons from mice treated with PBS or FTY720 from days 1–140 or from days 51–120 as indicated in Figure 6 were stained with Ki-67 antibody at the
end of the CAC (A), and percentage Ki-67 positive cells within colonic crypts was determined (B). Scale bar, 100 mm. Data are means ± SEM (n = 5). *p < 0.05,
**p < 0.001.
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of IECs, it regulates their survival by induction of antiapoptotic
genes during early tumor promotion and increases tumor inci-
dence (Greten et al., 2004). NF-kB also enhances chemokine
expression, leading to further recruitment of myeloid cells that
secrete proinflammatory cytokines, including IL-6 and TNF-a,
which as mentioned are the main drivers of CAC. Thus, NF-kB
can control STAT3 activation in IECs in a 3-fold manner: first,
by recruiting myeloid cells, most probably lamina propria
macrophages, dendritic cells, and T cells, that secrete STAT3-
activating cytokines; second, by controlling the transcription of
these cytokines in myeloid cells (Karin, 2009); and third, many
of these cytokines, such as TNF-a as well as IL-1, stimulate
SphK1 and upregulate its expression (Spiegel and Milstien,
2011), leading to further amplification of the activation of both
STAT3 (by ‘‘inside-out’’ signaling of S1P and ligation of S1PR1)
and NF-kB (by intracellular S1P) (Figure 8D).
Although NF-kB in immune cells is mainly protumorigenic in
CAC, the functions of STAT3 are more complex. Impaired
expression of STAT3 in myeloid cells results in enhanced colitis
(Takeda et al., 1999) and progression of CAC, possibly through
inhibition of IL-10 signaling (Deng et al., 2010). In contrast,
ablating STAT3 expression in a different colorectal cancer model
decreased tumor incidence and progression by decreasing
IL-17 production (Wu et al., 2009). Similarly, inhibiting STAT3
signaling in the hematopoietic system elicits multicomponent
antitumor immunity (Kortylewski et al., 2005). It has also been
suggested that STAT3-S1PR1 upregulation in myeloid cells
and persistent STAT3 activation can increase their proliferation
and survival and promote intravasation, which might facilitate
colonization in future metastatic sites (Deng et al., 2012).
Like induction of NF-kB and STAT3 transcriptional programs
in cancer, the most common mechanism by which SphK1
activity is increased is not through activating mutations, but116 Cancer Cell 23, 107–120, January 14, 2013 ª2013 Elsevier Inc.rather by an excess of activating cytokines provided in an
autocrine or paracrine manner. It has previously been shown
that STAT3 activation and S1PR1 abundance are increased in
both tumor cells and in the tumor microenvironment (Lee et al.,
2010), further supporting a noncell autonomous activation of
STAT3. Likewise, SphK1 was upregulated in CAC adenomas
and in inflammatory cells in the tumor microenvironment, even
more so in Sphk2/ mice (Figure 8B), and also in the mucosa
and lamina propria of patients with UC (Snider et al., 2009) and
human colorectal cancers (Kawamori et al., 2009). Although
S1P is maintained at low levels in most tissues, its abundance
in the colon and circulation is congruently increased during
chronic inflammation and in the tumor microenvironment (Naga-
hashi et al., 2012). Altered epithelial and neoplastic cells and re-
cruited immune cells continue to produce S1P as well as cyto-
kines (e.g., IL-6) (Bollrath et al., 2009; Grivennikov et al., 2009)
that activate oncogenic STAT3 to sustain tumor-associated
inflammation and to fuel tumor initiation, promotion, and
progression.
Little is known about transcriptional regulation of Sphk1. We
have shown that like SphK1, c-Jun, a component of the AP-1
transcription factor that regulates transcription of Sphk1, was
also increased in the colons of Sphk2/mice. SphK2 is present
in the nucleus of many types of cells and its ablation reduces
nuclear levels of S1P, an endogenous inhibitor of HDAC1/2,
and consequently influences expression of specific genes
(Hait et al., 2009). In this regard, it has been demonstrated that
inhibition of HDACs suppresses induction of c-Jun transcription
by blocking the recruitment of the preinitiation complex to the
c-Jun promoter (Yamaguchi et al., 2005). In agreement, we
found that HDAC inhibitors reduce expression of both c-Jun
and Sphk1. Our data imply that deletion of Sphk2 and lack of
HDAC inhibition by S1P increases the induction of c-Jun and
its target gene Sphk1. Given the significance of c-Jun in cell
Figure 8. Treatment with FTY720 during Late Stage of CAC Attenuates STAT3 Activation and Expression of SphK1 and S1PR1
(A–C) Immunohistochemical analysis of phospho-STAT3 (A), SphK1 (B), and S1PR1 (C) in CAC tumors fromWT and Sphk2/ mice treated with PBS or FTY720
from day 51–120. Scale bar, 100 mm.
(D) Proposed model for the role of SphK1/S1P/S1PR1 axis in a feed-forward amplification loop leading to NF-kB and persistent STAT3 activation. SphK1 is
upregulated in colitis and CAC, producing S1P. Extracellular S1P activates S1PR1, which induces STAT3 activation at least in part via Src. Reciprocally, STAT3
enhances transcription of its target genes, including S1PR1. Intracellular S1P is also involved in NF-kB activation, which regulates transcription of proin-
flammatory cytokines such as TNF-a and IL-6. IL-6 induces STAT3 activation. TNF-a also can stimulate SphK1 to amplify NF-kB activation. Treatment with
FTY720 reduces upregulation of both SphK1 and S1PR1. Note: this simplified scheme is notmeant to imply that all of these loops occur within a single type of cell.
See also Figure S5.
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another potential mechanism to control SphK1 expression in
cancer.
The importance of the SphK1/S1P/S1PR1 amplification loop
is highlighted by our findings that FTY720, which reverses the
upregulation of SphK1 and S1PR1, also prevents recruitment
of immune cells, excessive proinflammatory cytokine production
(in particular, IL-6 and TNF-a), and persistent NF-kB and STAT3
activation leading to severe colitis and CAC. Unexpectedly,
however, FTY720 was also effective in Sphk2/ mice, in con-
trast to previous studies indicating that SphK2 was the sole
enzyme responsible for phosphorylating FTY720 in vivo to the
active S1PR1 modulator (Kharel et al., 2005; Sensken et al.,
2009). However, this was based on the inability of a single
dose of FTY720 to induce lymphopenia in Sphk2/ mice.
Because it was previously shown that FTY720 was also a weak
substrate for SphK1 (Billich et al., 2003; Paugh et al., 2003), itCappears that upregulation of SphK1 can compensate for the
lack of SphK2.
In agreement with their immunosuppressive actions, FTY720
and other S1PR1 modulators are efficacious in several different
models of colitis (Daniel et al., 2007; Deguchi et al., 2006).
Although targeting the inflammatory microenvironment may be
beneficial because immune cells are not subject to the same
mechanisms of drug resistance as cancer cells, anti-inflamma-
tory therapies do not kill cancer cells. Treatment with FTY720,
however, blocked CAC progression even when only adminis-
tered after tumors were initiated, and thus has cytostatic effects
on cancer cells that are independent of immunosuppression.
In agreement, FTY720 inhibits proliferation and enhances
apoptosis of several types of cancer cells in vitro and suppresses
xenograft tumor growth and metastasis in immunodeficient
mice (Pyne and Pyne, 2010). Our work shows that FTY720, by
interfering with the upregulation of both SphK1 and S1PR1,ancer Cell 23, 107–120, January 14, 2013 ª2013 Elsevier Inc. 117
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that leads to NF-kB and persistent STAT3 activation critical for
CAC. These results also indicate that targeting the upstream
machinery leading to STAT3 activation is a feasible alternative
approach to inhibit this signaling pathway and has broad impli-
cations for pathogenesis and treatment of colitis-associated
colorectal cancer in patients with IBD.
EXPERIMENTAL PROCEDURES
Mice and CAC Protocol
C57BL/6 WT and Sphk2/ mice were from R. Proia. Six-to-eight week old
mice with littermate controls to ensure the same genetic background were
used for all experiments. Animal procedureswere approved by the Institutional
Animal Care and Use Committee at Virginia Commonwealth University. CAC
was induced as described (Grivennikov et al., 2009). Briefly, mice were in-
jected intraperitoneally (i.p.) with 10 mg/kg azoxymethane (AOM; Sigma) and
after 5 days, received drinking water containing 2.5% DSS for 5 days. Mice
were then given regular drinking water for 14 days, followed by two additional
DSS treatment cycles (Figure 1A). Colons were removed on day 140 and
flushed with PBS, and tumors were counted. Macroscopic tumors were
measured with calipers and software for microscopic tumors. Portions of the
distal colons were either frozen in liquid nitrogen or fixed with 10% formalin
and paraffin embedded for histological analyses.
Induction and Analysis of Acute Colitis
Acute colitis was induced with 5% DSS for 5 days. In some experiments, mice
were given PBS or FTY720 (0.3 mg/kg) orally daily during colitis regimen. The
clinical course was followed daily by measurements of body weight and moni-
toring signs of rectal bleeding and diarrhea and was scored as described
(Siegmund et al., 2001). Histological assessments of colitis and severity scores
were made in a double-blinded manner after hematoxylin and eosin (H&E)
staining as described (Williams et al., 2001).
Immunohistochemistry Analysis
Paraffin-embedded slides were deparaffinized, and antigen unmasking was
carried out by microwave heating in citrate buffer for 20 min. Slides were incu-
bated with 3% H2O2 and then goat or horse serum (DAKO) for 30 min at room
temperature. After washing with PBS, slides were incubated with primary
antibodies at 4C overnight. Biotinylated secondary anti-rat or anti-rabbit
antibodies were added and incubated at room temperature for 1 hr. After
30 min with streptavidin-HRP, sections were stained with DAB substrate
and counterstained with H&E. Primary antibodies used were anti-Ki-67
(DAKO), anti-COX-2 and anti-p-STAT3 (Cell Signaling), anti-S1PR1 (Santa
Cruz), anti-IL-6 and anti-SphK1 (Abcam).
Bone Marrow Chimeras
Bone marrows from femurs and tibia were collected from Sphk2+/+ congenic
mice (expressing CD45.1 leukocyte antigen) and Sphk2/ (expressing
CD45.2 leukocyte antigen) donor mice, and cells were resuspended in PBS
after washing. The recipients, which were given acidified, antibiotic-treated
drinking water for 2 weeks, were irradiated and then injected i.v. with 5 3
106 donor cells. Bone marrow reconstitution efficiency was verified after
6 weeks by staining for CD45.1 and CD45.2 in blood cells using FITC-conju-
gated anti-CD45.1 and PE-conjugated anti-CD45.2 (Biolegend).
Sphingolipid Analyses
Lipids were extracted from colons and serum, and phosphorylated and
unphosphorylated sphingoid bases were quantified by liquid chromatography,
electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) as
described (Hait et al., 2009).
Statistical Analysis
Experiments were repeated at least three times with consistent results.
Results were analyzed for statistical significance with the Student’s t test
for unpaired samples in Excel (Microsoft), and p < 0.05 was considered
significant.118 Cancer Cell 23, 107–120, January 14, 2013 ª2013 Elsevier Inc.SUPPLEMENTAL INFORMATION
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